



EmphyCorp Rx Nasal Spray Expanded Phase III Clinical Trial for Long COVID is added to the N115 Drug Pipeline

Flemington, NJ –March 7, 2024 - EmphyCorp Inc. www.EmphyCorp.com, a private corporation, with several late stage drugs, specializes in Rx Non-Steroidal Nasal and Oral Spray Technology for the treatment of Interstitial Lung Disease (orphan drug designation), Core Respiratory Diseases, Allergic Rhinitis, Long COVID, Flu, and COVID-19.

The Patented N115 Technology Platform has demonstrated efficacy, with no known side effects, in 23 human clinical studies for all lung and sinus diseases tested including COPD, Interstitial Lung Disease (Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis), Long COVID, Allergic Rhinitis, Chronic Rhinitis, and Sinusitis. Our Drug Pipeline also includes treatments for Pulmonary Hypertension.

EmphyCorp/Cellular Sciences has added an Expanded Phase III Clinical Trial for our Rx Nonsteroidal Nasal Spray with no known side effects for Long COVID to the Rx N115 Nasal and Oral Spray Drug Pipeline.

A prior successful Rx N115 Nasal Spray Phase III Clinical Trial for Long COVID was completed, and the results were published in a European Journal of Respiratory Medicine Peer Review, along with Phase III results for treating Patients with Interstitial Lung Disease (Pulmonary Fibrosis with COPD and Idiopathic Pulmonary Fibrosis) and COVID-19. **Peer Review:** [Inhalation-of-Sodium-Pyruvate-to-Reduce-the-Symptoms-and-Severity-of-Respiratory-Diseases-Including-COVID-19-Long-COVID-and-Pulmonary-Fibrosis-110921.pdf](https://www.EmphyCorp.com/peer-review-inhalation-of-sodium-pyruvate-to-reduce-the-symptoms-and-severity-of-respiratory-diseases-including-covid-19-long-covid-and-pulmonary-fibrosis-110921.pdf) (emphycorp.com).

In each Clinical Trial, N115 produced statistically significant increases in all lung functions with the reduction in nasal and respiratory inflammation, a reduction in oxygen radicals, congestion, coughing, fatigue, and a reduction of inflammatory cytokines including IL-6, a cause of the cytokine storm in COVID-19 patients. N115 also increases the synthesis of nasal nitric oxide, a natural defence molecule that kills invading bacteria, fungi, and viruses to prevent and reduce the severity of infections.

EmphyCorp/Cellular Sciences is nearing completion of an Expanded US Phase III Clinical Trial with our Rx N115 Nonsteroidal Nasal Spray in Idiopathic Pulmonary Fibrosis (IPF) for Coughing and Improved Lung Function (secondary medical endpoint).

The Phase III Clinical Trial for IPF and Long COVID Phase III Clinical Trial Results are both listed on www.ClinicalTrials.Gov under Cellular Sciences (Listed as Sponsor): <https://www.clinicaltrials.gov/search?spons=Cellular%20Sciences,%20inc>.

Latest Publication: European Journal of Respiratory Medicine Peer Review of Inhaled Sodium Pyruvate Reduces Lung Inflammation and Fibrosis in a Bleomycin Rat Model with N115 was published on January 9, 2024. [EmphyCorp-EJRP-Peer-Review-Inhaled-Sodium-Pyruvate-Reduces-Lung-Inflammation-and-Fibrosis-in-a-Bleomycin-Rat-Model-010924.pdf](https://www.EmphyCorp.com/peer-review-inhaled-sodium-pyruvate-reduces-lung-inflammation-and-fibrosis-in-a-bleomycin-rat-model-010924.pdf)

EmphyCorp has 5 Peer Reviewed articles and 8 Drug Patents including (3) new Composition Drug Patents for the treatment of:

- Apoptosis of Myofibroblasts (Slowing/stopping fibrosis/scarring of the lungs)
- Hypoxemia (low oxygen) & Dyspnea (shortness of breath) and Coughing
- Coronavirus/Influenza

COVID-19 and Long COVID Results

Given our success in treating Pulmonary Fibrosis patients and the other respiratory diseases, our research focused on treating the severe symptoms in COVID-19 infected patients and in Long COVID patients. In both cases N115 Nasal Spray produced statistically and clinically significant results by reducing hypoxemia that increased SaO2 levels in these patients. N115 Nasal Spray also significantly decreased dyspnea (shortness of breath), fatigue, coughing/sneezing, trouble breathing, body aches, and headaches, especially in Long COVID patients.

Phase III Clinical Trials have been successfully completed for Patients with Pulmonary Fibrosis and Idiopathic Pulmonary Fibrosis (IPF)

- The data showed that coughing episodes per day were significantly reduced in all patients on day 8 by 30% ($p=0.007$) and continued to decrease on day 14 by 55% ($p=0.0001$) and on the 22nd day of the trial, coughing decreased by 59% ($p=0.0001$).
- This correlated with a significant ($p=0.010$) improvement in nasal irritation/erythema with most patients being free of irritation by day 22 ($p<0.001$); and a significant ($p=0.010$) increase in the group average expelled NO by day 8. A significant ($p=0.010$) improvement in lung function (breathing) was observed in all patients with IPF by day 1, increasing to $p=0.0005$ by day 22 compared to their baseline therapies, determined by changes in FVC, FEV₁, PEF, and FEV₁/FVC ratios.
- The improved FEV₁/FVC ratio from 52% to 86% was clinically significant and indicated that current therapies in use are inadequate to treat patient with IPF.

EmphyCorp N115 Nasal Sprays have also been used to treat over 3 million patients globally in 200 hospitals, with no adverse events.

Dr. Alain Martin (CEO) created the EmphyCorp Patented Nasal and Oral Sprays, as well as Advanced Neosporin, Advanced Lubriderm, Early Pregnancy Test (EPT), Cool Mint Listerine, plus discovering the use of Rx Rezulin Drug for Type II Diabetes earlier in his career at Warner Lambert (Pfizer acquisition). He also created patented OTC and Rx products including next generation triple antibiotic, skincare, drug free post laser aftercare lotion with a cooling gel for pain, patented pet anxiety product (OTC or Rx) with no side effects for our sister company North Cell Pharmaceutical www.NorthCellPharma.com.

An Up-to-date Rx N115 Nasal Spray and Oral Spray Drug Pipeline, Peer Reviews, and Press Releases can be found on the EmphyCorp website www.EmphyCorp.com.

Please contact Robert Millar for more information and Partnership interest at 973-586-4421 or EmphyCorp@optonline.net.
